

David E Gloriam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4454445/publications.pdf>

Version: 2024-02-01

88
papers

8,286
citations

108046

37
h-index

60403

85
g-index

102
all docs

102
docs citations

102
times ranked

10295
citing authors

#	ARTICLE	IF	CITATIONS
1	Ligand-directed bias of G protein signaling at the dopamine D2 receptor. <i>Cell Chemical Biology</i> , 2022, 29, 226-238.e4.	2.5	14
2	The G protein database, GproteinDb. <i>Nucleic Acids Research</i> , 2022, 50, D518-D525.	6.5	49
3	Community guidelines for GPCR ligand bias: IUPHAR review 32. <i>British Journal of Pharmacology</i> , 2022, 179, 3651-3674.	2.7	84
4	Common coupling map advances GPCR-G protein selectivity. <i>ELife</i> , 2022, 11, .	2.8	59
5	Effector membrane translocation biosensors reveal G protein and β 2-arrestin coupling profiles of 100 therapeutically relevant GPCRs. <i>ELife</i> , 2022, 11, .	2.8	101
6	Molecular insights into ligand recognition and G protein coupling of the neuromodulatory orphan receptor GPR139. <i>Cell Research</i> , 2022, 32, 210-213.	5.7	13
7	Structure of the class D GPCR Ste2 dimer coupled to two G proteins. <i>Nature</i> , 2021, 589, 148-153.	13.7	55
8	GPCRdb in 2021: integrating GPCR sequence, structure and function. <i>Nucleic Acids Research</i> , 2021, 49, D335-D343.	6.5	254
9	Targeting the APP-Mint2 Protein-Protein Interaction with a Peptide-Based Inhibitor Reduces Amyloid- β Formation. <i>Journal of the American Chemical Society</i> , 2021, 143, 891-901.	6.6	15
10	Structural insights into the lipid and ligand regulation of serotonin receptors. <i>Nature</i> , 2021, 592, 469-473.	13.7	138
11	Structural Determinants for the Mode of Action of Imidazopyridine DS2 at β -Containing β 3-Aminobutyric Acid Type A Receptors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4730-4743.	2.9	6
12	Molecular Determinants Underlying Delta Selective Compound 2 Activity at β -Containing GABA _A Receptors. <i>Molecular Pharmacology</i> , 2021, 100, 46-56.	1.0	2
13	Structural dynamics bridge the gap between the genetic and functional levels of GPCRs. <i>Current Opinion in Structural Biology</i> , 2021, 69, 150-159.	2.6	6
14	GPCR activation mechanisms across classes and macro/microscales. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 879-888.	3.6	98
15	An online GPCR structure analysis platform. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 875-878.	3.6	16
16	A novel red fluorescence dopamine biosensor selectively detects dopamine in the presence of norepinephrine in vitro. <i>Molecular Brain</i> , 2021, 14, 173.	1.3	15
17	Pharmacology and function of the orphan GPR139 G protein-coupled receptor. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 35-46.	1.2	17
18	G protein-coupled receptor pharmacology-The next generation. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 3-4.	1.2	2

#	ARTICLE	IF	CITATIONS
19	Novel approaches leading towards peptide GPCR de-orphanisation. <i>British Journal of Pharmacology</i> , 2020, 177, 961-968.	2.7	30
20	Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists. <i>Molecular Cell</i> , 2020, 80, 485-500.e7.	4.5	111
21	GPCRmd uncovers the dynamics of the 3D-GPCRome. <i>Nature Methods</i> , 2020, 17, 777-787.	9.0	90
22	Delineation of molecular determinants for FR900359 inhibition of Gq/11 unlocks inhibition of G $\beta\gamma$ s. <i>Journal of Biological Chemistry</i> , 2020, 295, 13850-13861.	1.6	11
23	Combinatorial expression of GPCR isoforms affects signalling and drug responses. <i>Nature</i> , 2020, 587, 650-656.	13.7	87
24	The European Research Network on Signal Transduction (ERNEST): Toward a Multidimensional Holistic Understanding of G Protein-Coupled Receptor Signaling. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 361-370.	2.5	15
25	Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABA _A receptors. <i>Scientific Reports</i> , 2020, 10, 10078.	1.6	10
26	Probing the Existence of a Metastable Binding Site at the β_2 -Adrenergic Receptor with Homobivalent Bitopic Ligands. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7806-7839.	2.9	9
27	Discovery of Human Signaling Systems: Pairing Peptides to G Protein-Coupled Receptors. <i>Cell</i> , 2019, 179, 895-908.e21.	13.5	157
28	Bigger is better in virtual drug screens. <i>Nature</i> , 2019, 566, 193-194.	13.7	31
29	An online resource for GPCR structure determination and analysis. <i>Nature Methods</i> , 2019, 16, 151-162.	9.0	108
30	Five-Membered <i>N</i> -Heterocyclic Scaffolds as Novel Amino Bioisosteres at β_3 -Aminobutyric Acid (GABA) Type A Receptors and GABA Transporters. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 5797-5809.	2.9	20
31	Identification of a novel scaffold for a small molecule GPR139 receptor agonist. <i>Scientific Reports</i> , 2019, 9, 3802.	1.6	10
32	Rational design of a heterotrimeric G protein β subunit with artificial inhibitor sensitivity. <i>Journal of Biological Chemistry</i> , 2019, 294, 5747-5758.	1.6	32
33	Discovery of 2-(Imidazo[1,2- <i>b</i>]pyridazin-2-yl)acetic Acid as a New Class of Ligands Selective for the β_3 -Hydroxybutyric Acid (GHB) High-Affinity Binding Sites. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2798-2813.	2.9	12
34	Receptor selectivity between the G proteins G β_{12} and G β_{13} is defined by a single leucine-to-isoleucine variation. <i>FASEB Journal</i> , 2019, 33, 5005-5017.	0.2	23
35	5-HT _{2C} Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology. <i>Cell</i> , 2018, 172, 719-730.e14.	13.5	185
36	GPCRdb in 2018: adding GPCR structure models and ligands. <i>Nucleic Acids Research</i> , 2018, 46, D440-D446.	6.5	421

#	ARTICLE	IF	CITATIONS
37	Pharmacogenomics of GPCR Drug Targets. <i>Cell</i> , 2018, 172, 41-54.e19.	13.5	464
38	Structural Mapping of Adenosine Receptor Mutations: Ligand Binding and Signaling Mechanisms. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 75-89.	4.0	64
39	Structure-activity relationship and conformational studies of the natural product cyclic depsipeptides YM-254890 and FR900359. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 847-860.	2.6	24
40	The G protein-coupled receptor database, GPCRdb. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY27-2.	0.0	0
41	Structural insight to mutation effects uncover a common allosteric site in class C GPCRs. <i>Bioinformatics</i> , 2017, 33, 1116-1120.	1.8	9
42	The orphan G protein-coupled receptor GPR139 is activated by the peptides: Adrenocorticotrophic hormone (ACTH), β - MSH , and β -melanocyte stimulating hormone (β - MSH), and the conserved core motif HFRW. <i>Neurochemistry International</i> , 2017, 102, 105-113.	1.9	36
43	Development of a human vasopressin V1a-receptor antagonist from an evolutionary-related insect neuropeptide. <i>Scientific Reports</i> , 2017, 7, 41002.	1.6	33
44	Selectivity determinants of GPCR-G-protein binding. <i>Nature</i> , 2017, 545, 317-322.	13.7	297
45	Trends in GPCR drug discovery: new agents, targets and indications. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 829-842.	21.5	1,773
46	Molecular Hybridization of Potent and Selective β -Hydroxybutyric Acid (GHB) Ligands: Design, Synthesis, Binding Studies, and Molecular Modeling of Novel 3-Hydroxycyclopent-1-enecarboxylic Acid (HOCPA) and trans- β -Hydroxycrotonic Acid (T-HCA) Analogs. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9022-9039.	2.9	21
47	The GPR139 reference agonists 1a and 7c, and tryptophan and phenylalanine share a common binding site. <i>Scientific Reports</i> , 2017, 7, 1128.	1.6	25
48	Applying label-free dynamic mass redistribution assay for studying endogenous FPR1 receptor signalling in human neutrophils. <i>Journal of Pharmacological and Toxicological Methods</i> , 2017, 88, 72-78.	0.3	11
49	Identification of Histamine H3 Receptor Ligands Using a New Crystal Structure Fragment-based Method. <i>Scientific Reports</i> , 2017, 7, 4829.	1.6	10
50	Integrating structural and mutagenesis data to elucidate GPCR ligand binding. <i>Current Opinion in Pharmacology</i> , 2016, 30, 51-58.	1.7	52
51	Editorial overview: New technologies: GPCR drug design and function "exploiting the current (of) structures. <i>Current Opinion in Pharmacology</i> , 2016, 30, vii-x.	1.7	7
52	GPCRdb: the G protein-coupled receptor database "an introduction". <i>British Journal of Pharmacology</i> , 2016, 173, 2195-2207.	2.7	165
53	Total synthesis and structure-activity relationship studies of a series of selective G protein inhibitors. <i>Nature Chemistry</i> , 2016, 8, 1035-1041.	6.6	67
54	Novel Agonist Bioisosteres and Common Structure-Activity Relationships for The Orphan G Protein-Coupled Receptor GPR139. <i>Scientific Reports</i> , 2016, 6, 36681.	1.6	23

#	ARTICLE	IF	CITATIONS
55	GPCRdb: an information system for G protein-coupled receptors. <i>Nucleic Acids Research</i> , 2016, 44, D356-D364.	6.5	472
56	Selective Negative Allosteric Modulation Of Metabotropic Glutamate Receptors – A Structural Perspective of Ligands and Mutants. <i>Scientific Reports</i> , 2015, 5, 13869.	1.6	38
57	Generic GPCR residue numbers – aligning topology maps while minding the gaps. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 22-31.	4.0	387
58	Identification of the first surrogate agonists for the G protein-coupled receptor GPR132. <i>RSC Advances</i> , 2015, 5, 48551-48557.	1.7	8
59	Selective Allosteric Antagonists for the G Protein-Coupled Receptor GPRC6A Based on the 2-Phenylindole Privileged Structure Scaffold. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 8938-8951.	2.9	22
60	A new crystal structure fragment-based pharmacophore method for G protein-coupled receptors. <i>Methods</i> , 2015, 71, 104-112.	1.9	19
61	mGluR5: Exploration of Orthosteric and Allosteric Ligand Binding Pockets and Their Applications to Drug Discovery. <i>Neurochemical Research</i> , 2014, 39, 1862-1875.	1.6	29
62	Computer-Aided Discovery of Aromatic α -Amino Acids as Agonists of the Orphan G Protein-Coupled Receptor GPR139. <i>Journal of Chemical Information and Modeling</i> , 2014, 54, 1553-1557.	2.5	50
63	Structure-Activity Relationships and Identification of Optimized CC-Chemokine Receptor CCR1, 5, and 8 Metal-Ion Chelators. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 2863-2873.	2.5	2
64	3-Substituted 2-phenyl-indoles: privileged structures for medicinal chemistry. <i>RSC Advances</i> , 2013, 3, 945-960.	1.7	59
65	Design, Synthesis, and Pharmacological Characterization of <i>N</i> - and <i>O</i> -Substituted 5,6,7,8-Tetrahydro-4 <i>H</i> -isoxazolo[4,5- <i>d</i>]azepin-3-ol Analogues: Novel 5-HT _{2A} /5-HT _{2C} Receptor Agonists with Pro-Cognitive Properties. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 1211-1227.	2.9	50
66	Chemogenomics of allosteric binding sites in GPCRs. <i>Drug Discovery Today: Technologies</i> , 2013, 10, e307-e313.	4.0	8
67	The Contribution of Atom Accessibility to Site of Metabolism Models for Cytochromes P450. <i>Molecular Pharmaceutics</i> , 2013, 10, 1216-1223.	2.3	38
68	Structure-Activity Relationships of Constrained Phenylethylamine Ligands for the Serotonin 5-HT ₂ Receptors. <i>PLoS ONE</i> , 2013, 8, e78515.	1.1	9
69	Pharmacological Characterization and Modeling of the Binding Sites of Novel 1,3-Bis(pyridinylethynyl)benzenes as Metabotropic Glutamate Receptor 5-Selective Negative Allosteric Modulators. <i>Molecular Pharmacology</i> , 2012, 82, 929-937.	1.0	34
70	Modulation in Selectivity and Allosteric Properties of Small-Molecule Ligands for CC-Chemokine Receptors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 8164-8177.	2.9	27
71	Editorial [Hot Topic: Methods for the Successful Application of Chemogenomics to GPCR Drug Design (Guest Editors: Stephen L. Garland & David E. Gloriam)]. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1870-1871.	1.0	10
72	Chemogenomic Discovery of Allosteric Antagonists at the GPRC6A Receptor. <i>Chemistry and Biology</i> , 2011, 18, 1489-1498.	6.2	36

#	ARTICLE	IF	CITATIONS
73	G Protein- and Agonist-Bound Serotonin 5-HT _{2A} Receptor Model Activated by Steered Molecular Dynamics Simulations. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 315-325.	2.5	47
74	Present Perspectives on the Automated Classification of the G-Protein Coupled Receptors (GPCRs) at the Protein Sequence Level. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1994-2009.	1.0	8
75	A Ligands View of Target Similarity: Chemogenomic Binding Site- Directed Techniques for Drug Discovery. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1872-1881.	1.0	15
76	In Silico Identification of Novel G Protein-Coupled Receptors. <i>Neuroinformatics</i> , 2011, , 3-18.	0.2	0
77	A Community Standard Format for the Representation of Protein Affinity Reagents. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 1-10.	2.5	35
78	The SMARTCyp cytochrome P450 metabolism prediction server. <i>Bioinformatics</i> , 2010, 26, 2988-2989.	1.8	129
79	SMARTCyp: A 2D Method for Prediction of Cytochrome P450-Mediated Drug Metabolism. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 96-100.	1.3	233
80	The G protein-coupled receptor subset of the dog genome is more similar to that in humans than rodents. <i>BMC Genomics</i> , 2009, 10, 24.	1.2	47
81	Critical evaluation of the FANTOM3 non-coding RNA transcripts. <i>Genomics</i> , 2009, 94, 169-176.	1.3	15
82	Definition of the G Protein-Coupled Receptor Transmembrane Bundle Binding Pocket and Calculation of Receptor Similarities for Drug Design. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4429-4442.	2.9	100
83	Proteomic applications of automated GPCR classification. <i>Proteomics</i> , 2007, 7, 2800-2814.	1.3	40
84	The G protein-coupled receptor subset of the rat genome. <i>BMC Genomics</i> , 2007, 8, 338.	1.2	170
85	Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. <i>Genomics</i> , 2006, 88, 263-273.	1.3	354
86	The G Protein-Coupled Receptor Subset of the Chicken Genome. <i>PLoS Computational Biology</i> , 2006, 2, e54.	1.5	104
87	The human and mouse repertoire of the adhesion family of G-protein-coupled receptors. <i>Genomics</i> , 2004, 84, 23-33.	1.3	214
88	Selectivity Landscape of 100 Therapeutically Relevant GPCR Profiled by an Effector Translocation-Based BRET Platform. <i>SSRN Electronic Journal</i> , 0, , .	0.4	16